Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Ten claims about GLP-1 medications we get asked about. Each is fact-checked against primary sources. ClaimReview schema makes the page eligible for Google's fact-check carousel in search results.
Verdict: FALSE / misleading
GLP-1 receptor agonists slow gastric emptying as part of their mechanism — this is the action, not a complication. Some patients develop symptoms consistent with delayed emptying (nausea, early satiety, bloating); these are dose-dependent and usually resolve. True gastroparesis (a chronic condition with structural / neuropathic basis) is a different entity. The FDA has reviewed the safety signal and updated labeling for ileus. Use caution in patients with pre-existing gastroparesis.
Verdict: FALSE
Compounded semaglutide and Ozempic both contain semaglutide as the active ingredient. They are not the same product. Ozempic is FDA-approved, manufactured by Novo Nordisk under cGMP, and supplied in a calibrated pen injector. Compounded semaglutide is prepared by a licensed pharmacy under Section 503A or 503B and is not FDA-approved as a finished product. The active ingredient is identical; everything else (excipients, concentration, container, dose calibration) may differ.
Verdict: MISLEADING
Weight regain after stopping GLP-1 therapy is expected, not a sign of failure. STEP-4 showed that participants who stopped semaglutide regained much of the lost weight; those continuing maintained it. This reflects the chronic-disease framing of obesity: GLP-1s treat the underlying physiology while taken, but the physiology does not resolve. The clinical implication is that obesity treatment with GLP-1s is generally long-term, like hypertension or diabetes treatment.
Verdict: OVERSTATED
GLP-1 receptor agonists carry a boxed warning regarding medullary thyroid carcinoma based on rodent studies. Human evidence is limited; large epidemiologic studies have not shown a clear signal in humans. Patients with personal or family history of MTC or MEN-2 syndrome are contraindicated. For other patients, the warning is precautionary, not evidence-based. The risk-benefit calculation should be made with a clinician.
Verdict: FALSE
Nausea on GLP-1 therapy reflects the medication's mechanism (delayed gastric emptying), not toxicity. It is dose-dependent, typically peaks during titration, and resolves in most patients within 4–8 weeks of dose stability. Severe or persistent nausea warrants dose reduction or evaluation. The mechanism is the same as the satiety effect that drives weight loss.
Verdict: FALSE
Coverage varies. Most commercial plans cover Ozempic and Mounjaro for the type 2 diabetes indication. Coverage of Wegovy and Zepbound for chronic weight management is variable and frequently excluded on commercial plans. Medicare Part D excludes weight-management drugs by statute, though March 2024's cardiovascular indication for Wegovy created a coverage pathway for adults with BMI ≥27 and established CVD.
Verdict: FALSE
Compounded medications, including GLP-1 receptor agonists, are legal when prepared by a licensed pharmacy under Section 503A (for individual patients with valid prescriptions) or Section 503B (in bulk by a registered outsourcing facility, with restrictions). The legal framework is established by the Drug Quality and Security Act of 2013. The enforcement landscape changes as shortage status, ingredient compounding rules, and state pharmacy board actions evolve.
Verdict: FALSE
Semaglutide sold as a 'research chemical' or 'not for human use' from non-pharmacy sources is illegal, unregulated, and unverified. Prescribed compounded semaglutide is dispensed by a licensed pharmacy under a valid prescription, with the preparation made under USP standards. The risk profile of unregulated material is fundamentally different from that of prescribed compounded medication.
Verdict: MISLEADING
Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide is a single GLP-1 receptor agonist. The pharmacology is different, and the magnitude of effect is higher across most endpoints (weight, A1c, MASH endpoints in phase 2). But it is mechanistically a different molecule, not a higher-dose version of semaglutide.
Verdict: MISLEADING
GLP-1 receptor agonists produce meaningful weight loss in the majority of patients — 10–20% body weight at trial-level effect sizes. They do not eliminate the need for adequate protein intake, resistance training (especially in adults 40+), sleep, and clinical monitoring for side effects and contraindications. They are also generally long-term therapies; stopping leads to weight regain. None of this makes them less effective; it sets realistic expectations.
Each claim above is reviewed against an FDA document, peer-reviewed publication, or clinical guideline. The verdict reflects what the source evidence shows, not what is widely believed. See our fact-checking policy for the workflow.
Have a claim you want us to fact-check? Email editor@glponereview.com with the claim and where you encountered it. We add new claim reviews to this page periodically.